The reason might be because of "acquisition failed"
Medicare and patents aren't the only battles. Pushback from the US Federal Trade Commission is another hurdle for the industry. One recent example is the FTC's efforts, joined by several states, to stop Amgen's (AMGN) potential $28 billion acquisition of Horizon Therapeutics.
